Author:
Voderholzer Ulrich,Rubart Antonie,Kathmann Norbert,Staniloiu Angelica,Wahl-Kordon Andreas,Zurowski Bartosz
Publisher
Springer Berlin Heidelberg
Reference134 articles.
1. Ackerman, D. L., & Greenland, S. (2002). Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 22(3), 309–317. https://doi.org/10.1097/00004714-200206000-00012
2. Afshar, H., Roohafza, H., Mohammad-Beigi, H., Haghighi, M., Jahangard, L., Shokouh, P., Sadeghi, M., & Hafezian, H. (2012). N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 32(6), 797–803. https://doi.org/10.1097/JCP.0b013e318272677d
3. Afshar, H., Akuchekian, S., Mahaky, B., & Zarean, E. (2014). Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Research in Medical Sciences., 19(10), 976–981.
4. Ahmadpanah, M., Reihani, A., Ghaleiha, A., Soltanian, A., Haghighi, M., Jahangard, L., Sadeghi Bahmani, D., Holsboer-Trachsler, E., & Brand, S. (2017). Buprenorphine augmentation improved symptoms of OCD, compared to placebo – Results from a randomized, double-blind and placebo-controlled clinical trial. Journal of Psychiatric Research, 94, 23–28. https://doi.org/10.1016/j.jpsychires.2017.06.004
5. Akouchekian, S., Omranifard, V., Moshfegh, P., Maracy, M. R., & Almasi, A. (2018). The effect of atorvastatin on obsessive-compulsive symptoms of refractory obsessive-compulsive disorder (add-on therapy). Advanced Biomedical Research, 7, 90. https://doi.org/10.4103/abr.abr_114_16